CINCINNATI--(BUSINESS WIRE)--Meridian Bioscience, Inc., (NASDAQ:VIVO) announced that it has completed a license agreement with Eiken Chemical Co., Ltd., Japan, for its “LAMP” (Loop-mediated Isothermal Amplification) technology. The LAMP technology is a cutting-edge nucleic acid amplification method that is simple to perform, rapid, highly specific and performed at a single temperature. Unlike other amplification methods, no specialized equipment is necessary to perform the assay or to determine the final result. Results are typically obtained 1 hour after the start of the assay. This license agreement allows Meridian to apply the LAMP technology for the detection of infectious diseases in the United States and 18 other geographic markets.
